Article

Predicting risk of keratectasia after LASIK is difficult

Las Vegas-No current methodology can reliably predict which corneas will undergo keratectasia after refractive surgery.

"The best defense is clinician education, careful screening, a conservative refractive surgery exclusion strategy, and comprehensive disclosure of potential risks to the patient," said Stephen D. Klyce, PhD, during a refractive surgery subspecialty day presentation here at the American Academy of Ophthalmology annual meeting.

Forme fruste keratoconus is a known risk factor for refractive surgery. In an era in which the number of LASIK litigations is increasing and insurance costs are escalating, the need for careful preoperative screening has never been greater, said Dr. Klyce, professor of ophthalmology, Louisiana State University Health Sciences Center, New Orleans. He referred to a retrospective study of 10 eyes in seven patients in whom keratectasia developed after LASIK; each of these patients had a preoperative risk factor of either forme fruste keratoconus or low residual stromal bed thickness (<250 µm). Yet evidence also indicates that litigation can be successful even when no corneal abnormalities are detected.

"The incidence of keratectasia in patients with risk factors is unknown at this time," he said.

Contact lens history

Obtaining a contact lens history is one of the most critical steps in screening patients, Dr. Klyce said. Contact lens warpage must be excluded. Rigid and soft lenses can cause warpage by molding the cornea into patterns resembling keratoconus. If molding or warpage is apparent, the patient should discontinue wearing lenses and undergo repeat topography and refractions every 2 to 3 weeks until the cornea has normalized and is stable. Normalization may take several weeks for soft lenses and up to 6 months for rigid lenses.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.